FDA approves Inqovi for acute myeloid leukemia

🌐 Medical Xpress (IM) —
FDA approves Inqovi for acute myeloid leukemia

AI Summary

The U.S. Food and Drug Administration approved Taiho Oncology's Inqovi (decitabine and cedazuridine) plus venetoclax for treating adults aged 75 and older with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy. This approval offers a new treatment option for elderly AML patients.

The U.S. Food and Drug Administration has approved Taiho Oncology's Inqovi (decitabine and cedazuridine) plus venetoclax for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older or who are ineligible for intensive induction chemotherapy.

Markets Health FDA approval Inqovi acute myeloid leukemia AML treatment Taiho Oncology elderly patients

Read original source →